Aesica has successfully completed the validation of its high capacity manufacturing facility in Queenborough, UK, for commercial production. The
Aesica announced hat it has successfully completed the validation of its high capacity manufacturing facility in Queenborough, UK, for commercial production. The company invested $45 million in this new facility and has expanded commercial production of solid dosages for the treatment of type II diabetes.
The facility has been built with a capacity to produce in excess of 1 billion tablets annually, with future expansion plans to double production to more than 2.5 billion tablets. The advanced unit has been equipped with highly technical and specialist equipment including state-of-the-art spray granulators, coaters, tablet presses, powder handling systems and large capacity blenders. The facility provides a 10,000 m2 expansion to the existing Queenborough site and has a dedicated workforce of 55 technicians.
Source: Aesica
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.